AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05696314 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcervical Ultrasound
Description: Curved low-frequency ultrasound transducers will be placed on the submental region on the skin of the neck, and the tongue base will be visualized in the midline in transverse and sagittal planes. The tonsils will be visualized adjacent to the tongue base on either side in oblique transverse and oblique sagittal planes, deep to the submandibular glands.
Study NCT05542563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program (HMP) App
Description: The full HMP app includes 5 modules with practices designed to cultivate categories of mental and emotional skills linked to both hedonic and eudaimonic well-being. These include the cultivation of mindful attention (Awareness), positive relationships with self and others (Connection), insight into the nature of self and internal experience (Insight), and purpose, values, and meaning in life (Purpose), as well as an initial module which includes abbreviated introductions to the topics and lessons in all four areas (Foundations). For this study, the active intervention will include 4 weeks of training using the Foundations module followed by 4 weeks of training using the Awareness module.
Study NCT04877093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Pill
Description: The study will use a flexible-dose adjustment schedule to identify the minimum dose needed to alleviate symptoms while also ensuring acceptable adverse effects. In other words, all subjects will start at the minimum dose (0.1 mg/night). Near the end of every week, each subject will be assessed for symptom alleviation and adverse events by asking the patient two questions from the CAPS-5 (questions B2 and E6. At baseline, each patient will have scored a ≥3 on each of these questions. If one or both scores remain at ≥3 and if any reported adverse events are marked acceptable by both the clinician and subject, then the dosage for the following week will be increased one level according to the titration chart. However, if both scores for these questions are ≤2 and any current adverse events are acceptable, then the dosage will remain the same. Finally, if any adverse events are deemed unacceptable, the clonidine dosage will be reduced to the lowest acceptable daily dosage.
Study NCT04877093 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded placebo capsules will be provided to participants.
Study NCT06160752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles
Description: TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
Study NCT06160752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Description: TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
Study NCT06227962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assesment
Description: Estimated intelligence (subtasks of Wechsler Intelligence Scale for Children - Fifth edition -Dutch version \[WISC-V-NL\] or Wechsler Adult Intelligence Scale - Forth edition - Dutch version \[WAIS-IV-NL\]); Vienna reaction time; Rey auditory verbal learning test; Word fluency; Beery-Buktenica Developmental Test of Visual-Motor Integration, 6th Edition; Test of Everyday Attention for Children (TEA-Ch), subtask Score!/ or Test of Everyday Attention (TEA), subtask Elevator task; Trail making test; Word-color interference test
Study NCT06227962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Psychosocial functioning and quality of life (questionnaires)
Description: Anxiety (PROMIS); Depression (PROMIS); Peer-interaction (PROMIS); Perceived neurocognitive functioning (PROMIS); Participation and activity (PAY-CY); Trauma (KJTS/PCL-5); Health related quality of life (PEDSQL)
Study NCT06227962 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Parental psychosocial functioning (questionnaires)
Description: Anxiety (PROMIS); Depression (PROMIS); Distress Thermometer-Parents (DT-P); Trauma (PCL-5)
Study NCT05120648 — intervention group
Intervention type: BEHAVIORAL
Intervention: Biofeedback
Description: We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.
Study NCT04486833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quaratusugene ozeplasmid
Description: Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
Study NCT04486833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.
Study NCT04486833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-Based Chemotherapy
Description: Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.
Study NCT05721378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Permissive Weight Bearing group
Description: The Permissive Weight Bearing (PWB) protocol allows earlier post-operative permissive weight bearing, where progression of weight bearing is guided by the subjective experience (for example: pain, weight bearing tolerance) of the patient and the clinical expertise of the treating physician and therapist. Patients allocated to the PWB protocol start weight bearing after wound healing is achieved (approximately two weeks after the operation). Consequently, patients are stimulated to bear as much weight as tolerated by pain and comfort. Treatment will take place according to the PROMETHEUS protocol (treatment- and evaluation protocol). The protocol contains a number of weight bearing milestones (e.g. walking with two crutches, walking with two canes, walking with one cane and walking without any walking aids). The treating physiotherapist or physician records the dates that these milestones are reached in the study database.
Study NCT05721378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restricted Weight Bearing group
Description: The Restrictive Weight Bearing (RWB) protocol consists of 8 to 12 weeks of postoperative restricted weight (0-10%) bearing, following the current AO Guidelines (7). After 8 weeks of restricted weight bearing, the weight bearing will be increased with 25% per week for 4 weeks. Every time the patient and the treating physical therapist or physician have contact, the weight bearing advice given to the patient at that point in time is recorded (unloaded; partial weight bearing + clarification; full weight bearing). Also, any additional advice given to the patient is recorded.
Study NCT05632016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block (ESP)
Description: the erector spinae plane block will be performed bilaterally using a high-frequency-curved ultrasound transducer (Mindray 35C50EB, China) placed in a longitudinal orientation 3 cm lateral to the spinous process at two different levels, one above the angle of kyphosis at T8- T10 and another below the angle of kyphosis at L3. An 8- cm 22-gauge block needle (EchoStim; Benlan Inc, Oakville, Canada) is inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane below erector spinae muscle, the block will be performed by injection of 10 mL of bupivacaine at each point.A total volume of 40 ml of diluted bupivacaine with a total dose of 3mg/kg with variable concentrations according to body weight will be given for each patient.
Study NCT06539520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training program
Description: Aerobic training program; on interval moderate mode, 3 session per week, for 16 weeks, along 30-40 minutes, plus 5-10 minutes of warm up and 5 minutes cooling down, with 50-80% of maximal heart rate for each patient based on age. that progress every month by 10% directed by rating of perceived exertion.
Study NCT06539520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected physical therapy program for post stroke patients
Description: Selected neurorehabilitation for 1 hour session; 3 sessions per week, for 16 weeks. It involves weight shift side to side, reaching toward weak side, shoulder flexion overhead, shoulder external rotation, overhead press, shoulder internal rotation with Thera-band, heel slides, bridging, lying terminal knee extension, toe and heel raises, sensory reeducation exercises, and body awareness therapy.
Study NCT06023901 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Apical periodontitis
Description: Radiography of the patients were taken. Blood samples were collected from those patient
Study NCT06539520 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Selected physical therapy program for post stroke patients
Description: Selected neurorehabilitation for 1 hour session; 3 sessions per week, for 16 weeks. It involves weight shift side to side, reaching toward weak side, shoulder flexion overhead, shoulder external rotation, overhead press, shoulder internal rotation with Thera-band, heel slides, bridging, lying terminal knee extension, toe and heel raises, sensory reeducation exercises, and body awareness therapy.
Study NCT03786003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS
Description: Standard video assisted thoracic surgery, no use of rib-spreader.
Study NCT03786003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracotomy
Description: Standard thoracotomy
Study NCT04542642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reSET-O
Description: reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.
Study NCT04542642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAR-008
Description: PEAR-008 is a new, game-based version of reSET-O, a mobile application treatment for opioid use disorder.
Study NCT04928482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backward Walking Training
Description: Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
Study NCT04928482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Backward Walking Training
Description: Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
Study NCT04522180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHR-LRX
Description: GHR-LRX was administered by SC injection.
Study NCT04989075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral prophylactic intervention
Description: The oral prophylactic intervention will consist of the provision of specific package including a soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.
Study NCT04902222 — intervention group
Intervention type: DRUG
Intervention: Morphine
Description: Administration of 0.1 mg/kg (IBW) intravenous morphine
Study NCT06584682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-occipital muscle inhibition technique
Description: Therapist puts finger pads just beneath the superior nuchal line (below the occiput and above the C2 vertebra), and lifts the patient head slightly and apply an anterior force with cephalic traction on cervical spine this area. Then straighten the fingers to press the finger tips into muscle and hold until relaxation(30 sec) and then drop the head into palm in new position, give this technique in 10 rep/2 sets (each set have 5 repetitions).hot packs for 15 minutes prior to session, cervical muscle stretching,cervical mechanical traction for 8-10 minutes, force is applied 1/6th of the patient body weight, for C1-C2 at 0 degree of cervical flexion and for below C2 at 20 degree of cervical spine flexion and cervical muscle METs
Study NCT05401435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting measurement of blood pressure and heart rate
Description: Simultaneous blood pressure and heart rate measurement every morning and evening during the duration of the experiment (28 days).
Study NCT05779553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor Endothelial Marker 1 ( TEM1 ) by ELISA kits
Description: measurement of serum TEM1 in CRC patients, its relation to staging and comparing the diagnostic performance of serum TEM1 with serum CEA and CA19-9 for diagnosis of CRC. and Early detection of CRC patient
Study NCT06584682 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional therapy
Description: stretching of hamstring muscle, METs, sciatic nerve glides, lower limb neurodynamics.
Study NCT05646199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants will receive metformin
Study NCT05646199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Injectable Product
Description: Participants in this group will receive injectable Semaglutide
Study NCT04834778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-5404-FU
Description: HC 5404-FU (hemi fumarate salt of HC 5404) is a novel, highly selective, and potent PERK inhibitor. Preclinical pharmacological studies demonstrated high specificity of HC 5404-FU to PERK and decreased viability of tumor cells. HC 5404-FU will be orally administered BID every day with food or within 30 minutes of completing a meal, starting at 25 mg, with doses escalating to 50, 100, 200, 400, 600, and 900 mg BID as safety allows for each 3-week treatment cycle.
Study NCT06402851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulant Oral
Description: Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.
Study NCT06402851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant Oral
Description: Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.
Study NCT04088136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Everyday Metacognitive Memory Intervention
Description: Provides training in use of techniques and procedures to enhance proactive self-regulatory control over everyday memory demands, including strategies for learning information, planning for meeting everyday goals, and monitoring of efficacy of goal pursuit.
Study NCT04088136 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory Strategy Control Intervention
Description: Trains use of standard mnemonic techniques such as imagery and sentence generation for learning new associations and organizational and distinctiveness-based strategies for learning sets of items (e.g., word lists).
Study NCT06329674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-A51
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT06329674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A51R2
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT06329674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A51R3
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT06329674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-A51 Placebo
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT06329674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A51R2 Placebo
Description: Subjects take the investigational products once a day for 24 weeks.
Study NCT04952584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD30.CAR-EBVST cells
Description: The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10\^8 cells/m2 and we did not reach a MTD.~There will be a gap of 4 weeks between the first and second patient on each dose level.~On Day 0 of study, patients will receive their planned single dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.
Study NCT04728334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: An intravenous (IV) infusion of AK117 as monotherapy. All subjects will receive 4 weekly infusions (Days 1, 8, 15, and 22) of AK117 in each 28-day treatment cycle until unacceptable toxicity, documentation of confirmed progressive disease (PD), or subject withdrawal
Study NCT05463445 — intervention group
Intervention type: OTHER
Intervention: Only observation
Description: No intervention is needed.
Study NCT05577663 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine treatment of the extraction socket
Description: Suturing of the extraction socket with resorbable suture PGA 5/0 in order to protect the blood clot
Study NCT05577663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket seal technique by a free gingival graft
Description: Placement of a free gingival graft in the socket opening in order to protect and stabilize the blood clot followed by suturing
Study NCT05577663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket seal technique using a synthetic resorbable membrane
Description: Placement of a synthetic barrier in the socket opening in order to protect and stabilize the blood clot followed by suturing
Study NCT05959421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ERVEBO® (rVSV∆G-ZEBOV-GP)
Description: intramuscular vaccination
Study NCT03996044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teeth brushing and flossing
Description: All participants will be instructed to brush with dentifrice containing amine fluoride in their composition (Elmex®) and floss with dental flossing, 3 times a day after meals for 30 days.
Study NCT03996044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue scraping
Description: Tongue scraping will be performed by the same operator on all participants. Posterior-anterior movements will be performed with the scraper over the tongue dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
Study NCT05335577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Claudin-2
Description: A sequential non-invasive urinary molecular profiling for protein, i.e. Claudin-2 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
Study NCT05335577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary Caveolin-1
Description: A sequential non-invasive urinary molecular profiling for protein, i.e. Caveolin-1 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.
Study NCT05335577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary EGF
Description: A sequential non-invasive urinary molecular profiling for protein, i.e. epidermal growth factor (EGF) as potential marker for tight junction protective regulator, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity.
Study NCT03996044 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy (aPDT)
Description: One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
Study NCT03996044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Pharmacy-manipulated capsules containing strains of Lactobacillus salivarius WB21 (6.7 x 108 CFU) and xylitol (280mg) will be used. Forty-two capsules will be delivered for each patient, who should take 1 capsule 3 times a day after meals for 14 days.